Pneumocystis jiroveci Pneumonia in an Immunocompetent Female Patient

Lamyae Amro, Ghizlane Hamzaoui, Hafsa Sajiai, Hind Serhane, Abdelhaq Alaoui-Yazidi

Department of Respiratory Medicine, Laboratory PCIM, Faculty of Medicine and Pharmacy, Cadi Ayyad University, Marrakesh, Morocco
Email: ghizlanehamzaoui@hotmail.fr

Received 10 May 2014; revised 8 June 2014; accepted 7 July 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).

Abstract

Introduction: The pneumocystosis is an infection caused by a saprophytic germ Pneumocystis jiroveci. It is exceptional in immunocompetent patients. Case report: This is a 30-year-old patient, admitted to the service for an acute respiratory failure. She was treated for pulmonary tuberculosis 6 months ago. The review has objectified clinique cyanosis of the lips and extremities with a blood pressure 120/70 mmHg, a heart rate of 70 bats/min, a temperature of 38°C and SaO₂ to 82% in the open air. The chest radiograph objectified reticulonodular opacities on the right. The patient was put under bi-broad-spectrum antibiotics. Due to the non improvement of the patient’s state, the search for Pneumocystis jiroveci in induced sputum was made and it was positive. The search for a field of immunosuppression was negative.

Keywords
Pneumocystosis, Pneumocystis jiroveci, Immunocompetent

1. Introduction

The Pneumocystis jiroveci pneumonia is an opportunistic infection in which the infectious agent is Pneumocystis jiroveci, eukaryote belonging to the family of fungi. This opportunistic infection often occurs in the context of congenital or acquired immunodeficiency [1] [2]. We report the case of Pneumocystis jiroveci pneumonia in an immunocompetent female patient.

2. Clinical Observation

We report the case of Mrs Z.J. aged of 30 years, treated for smear-positive pulmonary tuberculosis 6 months ago, admitted to the department of pneumology for acute respiratory failure. The symptoms have appeared a week...
before with a productive cough with purulent sputum and right chest pain and dyspnea.

Clinique examination objectified cyanosis of the lips and extremities, blood pressure of 120/70 mmHg, a heart rate of 70 beats per minute, a temperature of 38°C and SaO₂ to 82% in air. The examination showed polypnea with 32 cycles per minute with crackles at the right chest and left aeric effusion syndrome.

The chest radiograph found reticulo-micro-nodular opacities on the right with lesions of emphysema on the left (Figure 1).

Chest CT scan confirmed the presence of bullous emphysema with air-fluid level in left and nodular opacities with bronchiectasis in right (Figure 2).

NFS objectified leukocytosis of 14,430 per mm³ with neutrophil granulocytes of 11,080 per mm³ and lymphocytes to 2080 per mm³. CRP was at 140.7 mg/l. Serum electrolytes objectified mild hyponatremia at 130 mmol/L, the BNP level was normal and fasting blood sugar was at 1.09 g/l.

The patient was put under amoxicillin clavulanic acid (3 g/day) and macrolide (500 mg/day for 3 days) and oxygen 6 L/min, without improvement.

A comprehensive assessment was performed including three sputum AFB smears and culture which are negative. The search for *Pneumocystis jiroveci* in induced sputum returned positive 2 times.
The patient was put under trimethoprim sulfamethoxazole orally (4 tablets per day) for 3 weeks and oral corticosteroids with good clinical outcome. The search of an immunosuppression was performed. The rapid HIV test and HIV serology were negative. The rates of CD4 and CD8 were normal. They were respectively 1880/mm³ and 732/mm³. The serum total protein was 67 g/l. The serum protein electrophoresis and immunoelectrophoresis were normal.

The diagnosis of *Pneumocystis carinii* pneumonia in an immunocompetent patient was made.

### 3. Discussion

The *Pneumocystis jiroveci* pneumonia is generally an opportunistic infection. It is exceptional in the immunocompetent [3]. For many years, *Pneumocystis jiroveci* pneumonia was considered as a result of reactivation of latent infection acquired in childhood [4] [5]. However, several factors have shown that reactivation of chronic infection is probably not the only cause and probably also a result of environmental exposure or interpersonal contamination. Moreover, the acquisition of *Pneumocystis jiroveci* is sometimes linked to airborne transmission from asymptomatic carrier or patients with *Pneumocystis carinii* pneumonia [4]. The *Pneumocystis jiroveci* pneumonia in patients without predisposing factors, like that described in the immune deficits other than AIDS [6] [7]. The main reported symptoms are hyperthermia in 60% - 90% of cases, dyspnea in 75% - 90% of cases and cough in 50% - 80% of cases. The time between onset of symptoms and diagnosis is relatively short, ranging from 1 to 14 days. Clinical examination reveals tachypnea and diffuse crackles at pulmonary auscultation. PaO₂ in ambient air is generally very decreased between 50 and 70 mm Hg. The *Pneumocystis jiroveci* pneumonia is more acute and severe in patients without HIV, with an array of acute respiratory failure often require the use of mechanical ventilation [4], which is consistent with the case of our patient. But evolution can be more insidious with a frustrated and slowly progressive symptoms, as reported in HIV infection [4] [8].

The x-ray findings of *Pneumocystis jiroveci* pneumonia are similar in HIV positive and negative patients. Typically, pulmonary involvement is often bilateral [4]. The X ray chest shows bilateral and diffuse interstitial opacities at the hilum. The radiography may be normal at a very early stage [3]. Classical elementary lesion objectified by CT scan is diffuse ground glass appearance whose distribution is heterogeneous sparing the cortex. Less obvious lesions as nodular opacities or cavity may be present. These atypical lesions may reflect a granulomatous reaction, but should evoke a cancer or other concomitant infection. This was the case in our patient.

Unlike HIV patients, cystic lesions are not described in HIV-negative patients with *Pneumocystis carinii* pneumonia [4].

The diagnosis requires the detection of *Pneumocystis carinii* by appropriate coloring on respiratory samples (Gomori-Grocott, Giemsa, toluidine blue, specific immunofluorescence) [9], or molecular biology with the identification of *Pneumocystis jiroveci* DNA by polymerase chain reaction [6].

These samples are often obtained by bronchoalveolar lavage with this is the reference method [9]. In specialized department, induced sputum by inhalation of hypertonic saline may be substituted bronchoalveolar lavage on first intention. This simple and noninvasive examination requires great rigor [9].

The first-line treatment of PCP is trimethoprim-sulfamethoxazole (TMP-SMZ) administered orally or intravenously to the respective doses of 15 to 20 mg/kg/d (TMP) and 75 to 100 mg/kg/day (SMZ), a total of 21 days [9]. When it cannot be used or has to be interrupted due to significant side effects, *Pentamidine isethionate* is an alternative [10]. Oxygen therapy should be adapted to hypoxemia and corticosteroids are indicated in pneumonia with moderate to severe hypoxia (PaO₂ less than 70 mmHg). Corticosteroids have more interest in pneumocystoses unrelated to HIV. That said, the risk of an associated latent viral infection is important [6]. The prognosis of this affection remains conditioned by the severity of lung damage and early effective treatment.

### 4. Conclusion

Through this observation, we insist on the importance of searching for *Pneumocystis jiroveci* in patients with febrile pneumonia with hypoxia, even in an immunocompetent patient.

### References


Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.